Navigation Links
Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Date:12/12/2007

Summary: An IND has Been Filed With the FDA for the Fourth Genmab Antibody

Developed Under the Company's Collaboration with Roche.

COPENHAGEN, December 12 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that an Investigational New Drug application (IND) for a Genmab antibody developed under the company's collaboration with Roche has been filed with the FDA by Roche. Genentech and Roche are collaborating on development of the antibody which selectively blocks the interaction of the OX40 ligand and its receptor. The companies are evaluating the antibody for the treatment of asthma. Genmab will receive a milestone payment from Roche which does not influence Genmab's financial guidance for 2007.

In pre-clinical data published in a recent article and commentary in The Journal of Clinical Investigation, treatment with the human OX40L blocking antibody led to significant therapeutic effects in a nonhuman primate model of allergic inflammation. The mechanisms of action of the human antibody include effective blockade of OX40L binding to its receptor, and depletion of cells expressing OX40L. Depletion of OX40L-expressing cells was shown to depend on interaction of immune effector cells with the therapeutic antibody. The observed in vivo efficacy of the OX40L-specific antibody may also involve restoration of peripheral tolerance mechanisms. Breaking of tolerance promotes development of autoimmune and allergic diseases.

Under the agreement with Roche, Genmab utilizes its broad antibody expertise and development capabilities to create human antibodies to a broad range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products. In certain circumstances, Genmab may obtain rights to develop products based on disease targets identified by Roche.

"Four of the antibodies developed by Genmab under our collaboration with Roche have now entered the clinic. We believe this
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
3. Dynatronics to Release Fourth Quarter and Year-end Results Friday, September 14, 2007; Conference Call set for 1:00 p.m. ET
4. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
5. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
6. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
7. Pharsight Hosts Fourth Annual PKS User Group Meeting
8. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
9. Monsanto Company Sets Webcast and Analyst/Media Call for 2007 Fourth-Quarter and Fiscal-Year Financial Results
10. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
11. Lilly Declares Fourth-Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BioPlus Specialty Pharmacy ... has an expanded team of Regional Pharmaceutical Care ... prescriber offices in their regions, with specific areas ... a variety of Regional Pharmaceutical Care Liaisons specializing ... hepatitis C help prescribers understand all the new ...
(Date:12/19/2014)... Reports from CDC show ... from one or more chronic health conditions - including ... address some of these diseases, but may not eliminate ... face. While implanted nerve stimulation devices today offer relief, ... which can induce side effects. , To eliminate ...
(Date:12/19/2014)... 18, 2014 With only 2 weeks ... special on Sartorius Biohit products . The product specials ... Picus Electronic Pipette Trade-in Program, and free pipette tips. ... officers around the world. They are ideal for lab ... include:, ,     Full volume range of 0.1 ...
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... held today. "This was a transformational year ... a promising future for our company," said Sergio ... past year, we have executed on key financial, human ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... Switzerland, December 19 An exclusive license,for the ... for,lung infections in Cystic Fibrosis patients was signed ... Japan transferred relevant,rights to Axentis Pharma AG of ... to the licensed technology and a phase II ...
... . , By means of X-ray interferometers, lengths ... resolution of less than one nm. The low translation velocity ... difficult, could now be increased by a factor of 100 ... , X-ray interferometers can measure lengths in the mm range ...
... DuPont today congratulated,growers planting Pioneer(R) brand sorghum hybrids ... in the 2007 National Sorghum Producers, (NSP),Yield and ... Pioneer sorghum,hybrid 84G62., Farmers growing Pioneer sorghum ... segments. First-, second- and third-place national,honors were awarded ...
Cached Biology Technology:Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections 2Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections 3Faster X-ray interferometers due to single-photon interference 2DuPont Congratulates Growers Planting Pioneer(R) Brand Sorghum Hybrids in Winning Majority of National Categories in Yield Contest 2
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
(Date:12/3/2014)... IRVINE, Calif. , Dec. 2, 2014 /PRNewswire/ ... of globally deployed, innovative test solutions for military, ... the newest version of its successful TS-900 ... the performance and features of high-end systems to ... with outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... jaw of a 120 million year old marine reptile suggest that ... The healed bite wounds were probably made by a member of ... behaviour of extinct sea creatures from the time of dinosaurs. The ... Polonica . Found in the remote desert near the town ...
... when cosmetics, shampoos, skin creams, and other personal care ... to plant-derived extracts and other natural ingredients government ... the silicone-based ingredients long used in these products. That,s ... of Chemical & Engineering News (C&EN), ACS, weekly newsmagazine. ...
... providing the inspiration for University of Adelaide computer science ... increase wind farm productivity. Senior Lecturer Dr Frank ... a "selection of the fittest" step-by-step approach called "evolutionary ... account wake effects, the minimum amount of land needed, ...
Cached Biology News:Battle scars found on an ancient sea monster 2Evolutionary lessons for wind farm efficiency 2
...
MOUSE ANTI S. NEWPORT SALMONELLA HADAR...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
Biology Products: